Pharmaceutical intermediates
Acalabrutinib Intermediates
6 pharmaceutical intermediates for Acalabrutinib. Indication: Mantle cell lymphoma; chronic lymphocytic leukemia; lymphocytic leukemia.
About Acalabrutinib
- Originator
- AstraZeneca; Acerta Pharma Ltd
- Indication
- Mantle cell lymphoma; chronic lymphocytic leukemia; lymphocytic leukemia
- Approved Date
- 10/31/2017
- DS/DP
- 07/11/2031
Available intermediates
6 intermediates currently listed for Acalabrutinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-Butynoic Acid | 590-93-2 | / | / |
| 2-Butynoyl Chloride | 39753-54-3 | / | / |
| 3-Chloro-2-pyrazinemethanamine hydrochloride | 939412-86-9 | / | / |
| (S)-Benzyl 2-(8-amino-1-bromoimidazo[1,5 -a]pyrazin-3- yl)pyrrolidine-1-carboxylate | 1420478-88-1 | / | / |
| [4-[(Pyridin-2-yl)carbamoyl]phenyl]boronic acid | 850568-25-1 | / | / |
| 4-[8-Amino-3-(2S)-2-pyrrolidinylimidazo[1,5 -a]pyrazin-1-yl]-N-2- pyridinylbenzamide | 1420478-90-5 | / | / |
Building toward Acalabrutinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →